Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026) (IMAGE)
Caption
Figure 1.
The four mechanism-based therapeutic domains of the 2025–2026 glioblastoma multiforme (GBM) pipeline: molecular-targeted agents (EGFR, CDK4/6, RAS/MAPK, BRAF V600E, IDH), immunotherapies and vaccines, oncolytic and gene therapy, and metabolic/tumour microenvironment agents, with representative investigational drugs. Patient selection across all domains is guided by MGMT methylation, IDH mutation, EGFR amplification and BRAF V600E status.
Credit
Copyright: © 2026 Rahman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content